Skip to main content
main-content

19-05-2011 | Diabetes | Article

Vildagliptin good option for Type 2 diabetic Muslims during Ramadan

Abstract

Free abstract

MedWire News: Data from the VECTOR study suggest that the dipeptidyl peptidase (DPP)-4 inhibitor vildagliptin may be a good option for treating Muslim patients with Type 2 diabetes during Ramadan.

"Despite the recommendation for Muslim patients with Type 2 diabetes not to fast during Ramadan, many patients choose to do so," commented study author Anthony Barnett from the University of Birmingham in the UK.

"When we consider the number of Muslims in the UK, around 1.6 million, it is critical that clinicians ensure that their Muslim patients with Type 2 diabetes are receiving the most appropriate treatment during this time."

Barnett and colleagues compared the outcomes of 23 patients who were treated with vildagliptin 50 mg twice daily with 36 patients treated with a sulphonylurea over an approximate 16-week period. Both medications were added to metformin treatment.

The researchers collected data 16 weeks before and approximately 6 weeks after fasting.

As reported in the journal Current Medical Research and Opinion, the team found that no hypoglycemic events or severe hypoglycemic events occurred in patients treated with vildagliptin. This compared with 34 hypoglycemic and one severe hypoglycemic event in the sulphonylurea-treated group.

In addition, patients in the vildagliptin group had a significant reduction in glycated hemoglobin from baseline, from 7.6% to 7.2%, compared with no significant change in the sulphonylurea group.

The mean number of missed doses was also significantly less for vildagliptin than for sulphonylurea, at 0.2 versus 7.6.

Barnett and colleagues conclude that the real-life data from the VECTOR (Vildagliptin Experience Compared To gliclazide Observed during Ramadan) study demonstrate that vildagliptin combined with metformin is an effective treatment option for Muslim patients during the Ramadan fasting period with low risk for hypoglycemia.

MedWire (www.medwire-news.md) is an independent clinical news service provided by Springer Healthcare Limited. © Springer Healthcare Ltd; 2011

By Helen Albert